Mobic

Meloxicam

Symptomatic treatment of painful OA (arthrosis, degenerative joint disease), RA, ankylosing spondylitis.

OA 7.5 mg daily, may be increased to 15 mg daily. RA & ankylosing spondylitis 15 mg daily, may be reduced to 7.5 mg daily.

Should be taken with food.

Hypersensitivity to meloxicam, acetylsalicylic acid or NSAIDs. Peri-op pain in CABG surgery setting. Active or recent GI ulceration/perforation; active inflammatory bowel disease (Crohn's disease or ulcerative colitis); overt GI bleeding, recent cerebrovascular bleeding or established systemic bleeding disorders; severe uncontrolled heart failure. Severe hepatic insufficiency. Non-dialysed severe renal insufficiency. Pregnancy & lactation.

Discontinue use at 1st appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Patients w/ history of GI disease; other risk factors associated w/ PUD eg, alcoholism, smoking, corticosteroid therapy; CV disease or risk factors for CV disease; decreased renal blood flow or vol; dehydration, CHF; recent major surgical procedures leading to hypovolaemia. May mask symptoms of an underlying infectious disease. Not to be taken by patients w/ galactose intolerance eg, galactosaemia. Not to be co-administered w/ other NSAIDs. Concomitant use w/ anticoagulants, diuretic, ACE inhibitor or AIIA. May affect ability to drive & use machines. Hepatic cirrhosis, nephrotic syndrome, overt renal disease; end-stage renal failure on haemodialysis. May impair fertility. Not recommended in women of childbearing potential. Not to be used in childn & adolescents. Elderly, frail or debilitated patients.

Headache; abdominal pain, dyspepsia, diarrhoea, nausea, vomiting.

Increased risk of GI ulcers & bleeding w/ other prostaglandin synthetase inhibitors including glucocorticoids & salicylates. Increased risk of bleeding w/ oral anticoagulants, systemically-administered heparin, thrombolytics, anitiplatelet drugs, SSRIs. Increased lithium plasma levels. Increased plasma conc of methotrexate. Decreased IUD efficacy. Potential for acute renal insufficiency in dehydrated patients w/ diuretics. Reduced effect of antihypertensives eg, β-blockers, ACE inhibitors, vasodilators. Synergistic effect w/ AIIA. Faster elimination w/ cholestyramine. Enhanced nephrotoxicity of cyclosporine. Monitor for hypoglycaemia w/ oral antidiabetics eg, sulphonylureas, nateglinide. Not recommended w/ other NSAIDs. Closely monitor patients in concomitant use w/ pemetrexed.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AC06 - meloxicam ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, oxicams.

C